Tag: Bimekizumab

In clinical trials for Bimzelx, a higher incidence of suicidal ideation was observed in treated subjects compared to placebo. This and other important safety measures highlight the importance of understanding **what are the precautions for Bimzelx** before beginning treatment.

According to clinical trials, weight loss was not a reported side effect of Bimzelx. However, individuals taking this medication may experience indirect weight changes stemming from other side effects, most notably infections or inflammatory bowel disease (IBD), which can cause a decreased appetite and subsequent weight loss.

During clinical trials for plaque psoriasis, infections occurred in 36% of patients treated with Bimzelx compared to 23% in the placebo group through 16 weeks. Understanding **how safe is Bimzelx?** involves evaluating its full safety profile, which includes both common and rare but serious adverse reactions.

While searching for the cost of Bimzelx, it's important to know that this medication, known by the active ingredient bimekizumab-bkzx, is an injectable, not a tablet. The manufacturer-reported list price was approximately $7,922 per autoinjector or syringe as of January 2025, but your final out-of-pocket cost can vary drastically based on insurance and financial assistance programs.

As of late 2024, the U.S. Food and Drug Administration (FDA) has approved Bimzelx (bimekizumab) for multiple conditions, including plaque psoriasis and psoriatic arthritis. However, Bimzelx is a biologic medication, and for that reason, there is currently no generic for Bimzelx.

A 2024 study in *JAMA* estimated the median cost of bringing a new drug to market at nearly $1 billion, and for biologic drugs like Bimzelx, this figure can be even higher, contributing significantly to its expensive price. The high price tag of specialized medications is a significant barrier for many patients, prompting the question, 'Why is Bimzelx so expensive?'

Bimzelx is a biologic medication used for autoimmune conditions like psoriasis, and clinical trial data shows that up to 36% of patients experienced infections within the first 16 weeks of treatment. Understanding **who should not take Bimzelx** is critical to managing these risks and ensuring patient safety.

Plaque psoriasis affects an estimated 3% of adults in the United States, which translates to over 7.5 million people [1.9.1, 1.9.2]. For those exploring treatment options, understanding what is similar to Bimzelx is a crucial step in managing this chronic condition.

Affecting millions worldwide, moderate to severe plaque psoriasis requires effective treatment options [1.7.3]. In the debate of biologic medications, a key question for patients and clinicians is: Is Enbrel better than Bimzelx? This article examines the data behind these two prominent drugs.